Positron Corp. · OTC:POSC
Positron — Investor Presentation (May 2012)
19 slides from Positron's investor presentation, May 7, 2012
Slide 1: Positron and the Future of Nuclear Cardiology
Positron Positron and the Future of Nuclear Cardiology, May // 2012
Slide 2: Positron Corporation
Positron Corporation Positron Corporation is a leading molecular imaging healthcare company that is vertically integrating all the key segments of nuclear cardiology— offering a full solution for cardiac PET imaging. Positron provides innovative nuclear medicine technologies, radiopharmaceuticals an
Slide 3: Company Snapshot
Company Snapshot Industry Nuclear Medicine Ticker Symbol OTCBB : POSC Average Volume (3 month) [uam Shares Outstanding / Fully Diluted _| 1.18 / 3.08 Fully Diluted Market Cap $45M Estimated Revenue (2012) $7.0M
Slide 4: Objectives
Objectives If I/ I! // Become dominant market player within the nuclear cardiology industry through the vertical integration of all key components creating a end to end solution for nuclear cardiologists Positron will facilitate the stabilization, security and growth of the industry by increasing an
Slide 5: Vertical Integration Approach
Vertical Integration Approach Attrius + Only dedicated PET imaging system * Proprietary suftware * Posistar: clinical and technical support ‘Manufacturing and Distribution Rubidium-82 generator development and radiopharmaceutical manufacturing Posifix: a virtual nuclear pharmacy Strategic partnershi
Slide 6: Positron's Strategy
Positron’s Strategy Implement a vertically integrated solution for cardiac PET-to meet current and future demand. Sr-82 Production ‘Sr-82 Processing & Rb-82 PET System Services Waste Management Generator Offering an end-to-end solution that is redefining an industry.
Slide 7: Cardiac PET Supply Chain
Cardiac PET Supply Chain Positron seeks to build 70 Mev cyclotron; located in Indiana Target processing also performed by U.S. Gov. at Los Alamos Positron’s processing & recycling facilities; located in Texas One U.S. supplier of Rb-82 generators and carts: Bracco Diagn sitron and/or 3" party genera
Slide 8: Industry Overview
Industry Overview I I I I Cardiovascular disease (CVD) is the leading cause of death inthe US (34.2 %) Direct CVD costs are projected to increase from$316 billion in 2011 to $818 billion in 2030 (American Heart Association, 2011). The two dominant diagnostic modalities in cardiac nuclear medicine ar
Slide 9: Why PET Now?
Why PET Now? Paradigm Shift to Better Medicine // PET relative to SPECT hasa significantly higher rate of specificity and sensitivity resulting in decreased attenuation artifacts and inconclusive studies. PET provides a more accurate diagnosis for patients, potentially reducing unnecessary downstrea
Slide 10: Target Markets
Target Markets I I I I Target US Market for SPECT cardiac radiopharmaceuticals is $600-620 million and is expected to be flat in the nearest future. Cardiac PET equipment market is relatively small but fast growing and is expected to grow from $26 million to $47 million in 2015 or 20% every year (Mi
Slide 11: Core Products
Core Products Attrius® // Dedicated PET system optimized for myocardial perfusion imaging, that enables physicians to provide superior proven technology, while delivering an accurate diagnosis. PosiRx™ // Arevolutionary device that automates the elution, preparation and dispensing processes for radi
Slide 12: Positron's Integrated Solution
Positron’s Integrated Solution ATTRIUS POSISTAR RADIO- 70 MeV CYCLOTRON PHARMACEUTICALS RADIOISOTOPES Rb-82 GENERATOR Sr-82 handling & POSIRX jrtual nuclear pharmac
Slide 13: Competitive Advantages
Competitive Advantages I I II I I Attrius— only dedicated PET system in the world: proprietary software technology that will offer Coronary Flow Reserve (CFR) & low dose protocols. Sr-82 Capabilities— Positron possesses the only commercial resource in the world with practical knowledge and experienc
Slide 14: Positron Highlights
Positron Highlights i i i i i i Ul Acquired Manhattan Isotope Technologies (MIT) for the processing of radioisotopes supplied by foreign and domestic sources. Positron offered economic incentives to locate its 70 MeV cyclotron and corporate offices in Indiana. Positron’s Attrius & Attrius L systems
Slide 15: History and Projected Milestones
History and Projected Ping conhtero Milestones Sr-82 production to begin Expect availabilty of Rb-82 generator \ Launched Hositx Hadiopharmaceutical System Cyclotron project & TIFapproved Noblesville, IN Nuclear Pharmacy NRC approval Radiopharmaceutical production begins Acquisition of Manhattan Iso
Slide 16: Financial Projections
Financial Projections 2 350,000,000 300,000,000 250,000,000 $200,000.00 . Z 150,000,000 100,000,000 Ya $50,000.00 s * con 2082 em 2007 ei 2000 wave wzcane | sacess” | Sian? | senate | sessase Saas7e0n | Searesam | Saranms | s5746774 Poe E szzian0_| $1,253,000 | sazenow | ssex7.000 | $3337000 | s1070
Slide 17: Positron as an Investment
Positron as an Investment // Strong growth & industry adoption from SPECT to PET driven by paradigm shift in treatment and increased reimbursement for cardiac PET. // Positron is defining the cardiac PET industry. Positron has developed the only comprehensive integrated vertical solution // Expandin
Slide 18: Forward Looking Statements
Forward Looking Statements Certain statements contained in this presentation may constitute “forward- looking statements”. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical o
Slide 19: Positron: The Future of Nuclear Cardiology
Positron The Future of Nuclear Cardiology